Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | FSHR | P23945 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13021392 | 1.00 | GAA (0.35) | GAANFKB1NFKB2RELAMAPK10 | |
| SCHEMBL2670115 | 0.73 | GAA (0.33) | GAANFKB1NFKB2RELAMAPK10 | |
| SCHEMBL7394465 | 0.73 | HPGDS (0.40) | GAANFKB1NFKB2RELAMAPK10 | |
| SCHEMBL82732 | 0.71 | MEN1 (0.37) | GAAMEN1MAPK1KMT2A | |
| SCHEMBL740167 | 0.71 | MEN1 (0.37) | GAAMEN1MAPK1KMT2A | |
| SCHEMBL14019259 | 0.71 | GAA (0.35) | GAANFKB1NFKB2RELAMAPK10 | |
| SCHEMBL16493228 | 0.70 | GAA (0.40) | GAANFKB1NFKB2RELAMAPK10 | |
| SCHEMBL20887942 | 0.69 | CRBN (0.36) | GAANFKB1NFKB2RELAMAPK10 | |
| SCHEMBL27841938 | 0.68 | MEN1 (0.36) | GAANFKB1NFKB2RELAMEN1 | |
| SCHEMBL2087734 | 0.68 | RORC (0.43) | GAANFKB1NFKB2RELAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2000467-B1 | HYDRATE FOR MEDICAL PURPOSES | DAIICHI SANKYO CO LTD (JP) | 2014-10-01 | — | — | EP | disclosed |
| EP-2000467-B1 | HYDRATE FOR MEDICAL PURPOSES | DAIICHI SANKYO CO LTD (JP) | 2014-10-01 | — | — | EP | disclosed |
| EP-1882689-B1 | TRI- OR TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-8476429-B2 | Tri-, tetra-substituted-3-aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-02 | — | — | US | disclosed |
| US-8476429-B2 | Tri-, tetra-substituted-3-aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-02 | — | — | US | disclosed |
| US-8378119-B2 | Method for producing asymmetric tetrasubstituted carbon atom-containing compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-02-19 | — | — | US | disclosed |
| US-8378119-B2 | Method for producing asymmetric tetrasubstituted carbon atom-containing compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20120232288-A1 | TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120232288-A1 | TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120172605-A1 | METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-07-05 | — | — | US | disclosed |
| EP-2000467-A9 | HYDRATE FOR MEDICAL PURPOSES | Daiichi Sankyo Company, Limited (JP) | 2009-03-18 | — | — | EP | disclosed |
| US-20090054648-A1 | METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-02-26 | — | — | US | disclosed |
| US-20090054648-A1 | METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-2000467-A2 | HYDRATE FOR MEDICAL PURPOSES | Daiichi Sankyo Company, Limited (JP) | 2008-12-10 | — | — | EP | disclosed |
| EP-2000467-A2 | HYDRATE FOR MEDICAL PURPOSES | Daiichi Sankyo Company, Limited (JP) | 2008-12-10 | — | — | EP | disclosed |
| US-20080300403-A1 | Method for Production of Quinolone-Containing Lyophilized Preparation | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-12-04 | — | — | US | disclosed |
| EP-1930006-A1 | METHOD FOR PRODUCTION OF QUINOLONE-CONTAINING LYOPHILIZED PREPARATION | Daiichi Sankyo Company, Limited (JP) | 2008-06-11 | — | — | EP | disclosed |
| EP-1882685-A1 | METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-01-30 | — | — | EP | disclosed |
| EP-1882689-A1 | TRI- OR TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2008-01-30 | — | — | EP | disclosed |
| US-20060264428-A1 | Tri-, tetra-substituted-3-aminopyrrolidine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172605-A1 | METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND | DHPS, COASY, NQO2 | GAA 2069/4885NFKB1 3784/4885NFKB2 4206/4885 |
| US-20080300403-A1 | Method for Production of Quinolone-Containing Lyophilized Preparation | NQO2, TREH, CYP51A1 | GAA 438/4885NFKB1 1051/4885NFKB2 1918/4885 |
| US-20060264428-A1 | Tri-, tetra-substituted-3-aminopyrrolidine derivative | QTRT1, RRS1, LAS1L | GAA 3745/4885NFKB1 951/4885NFKB2 2016/4885 |
| US-20090054648-A1 | METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND | ACSL3, ARL1, NQO2 | GAA 1980/4885NFKB1 3028/4885NFKB2 2640/4885 |
| US-20120232288-A1 | TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE | TLR5, TEAD4, NAALAD2 | GAA 1156/4885NFKB1 196/4885NFKB2 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.